These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 33459118)

  • 1. Antibodies to watch in 2021.
    Kaplon H; Reichert JM
    MAbs; 2021; 13(1):1860476. PubMed ID: 33459118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to watch in 2022.
    Kaplon H; Chenoweth A; Crescioli S; Reichert JM
    MAbs; 2022; 14(1):2014296. PubMed ID: 35030985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to watch in 2020.
    Kaplon H; Muralidharan M; Schneider Z; Reichert JM
    MAbs; 2020; 12(1):1703531. PubMed ID: 31847708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to watch in 2018.
    Kaplon H; Reichert JM
    MAbs; 2018; 10(2):183-203. PubMed ID: 29300693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to watch in 2017.
    Reichert JM
    MAbs; 2017; 9(2):167-181. PubMed ID: 27960628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to watch in 2023.
    Kaplon H; Crescioli S; Chenoweth A; Visweswaraiah J; Reichert JM
    MAbs; 2023; 15(1):2153410. PubMed ID: 36472472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to watch in 2019.
    Kaplon H; Reichert JM
    MAbs; 2019; 11(2):219-238. PubMed ID: 30516432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
    Ghadanian M; Schafheutle E
    Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to watch in 2015.
    Reichert JM
    MAbs; 2015; 7(1):1-8. PubMed ID: 25484055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An EUA for bamlanivimab and etesevimab for COVID-19.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966
    [No Abstract]   [Full Text] [Related]  

  • 14. An EUA for sotrovimab for treatment of COVID-19.
    Med Lett Drugs Ther; 2021 Jun; 63(1627):97-xx98. PubMed ID: 34181630
    [No Abstract]   [Full Text] [Related]  

  • 15. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
    Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC
    Trials; 2021 May; 22(1):363. PubMed ID: 34034784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
    Goel B; Bhardwaj N; Tripathi N; Jain SK
    Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

  • 18. Casirivimab/Imdevimab: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fighting COVID-19 with Artificial Intelligence.
    Monteleone S; Kellici TF; Southey M; Bodkin MJ; Heifetz A
    Methods Mol Biol; 2022; 2390():103-112. PubMed ID: 34731465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing Antibody Therapeutics for COVID-19.
    Hurt AC; Wheatley AK
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33916927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.